spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

PCI Pharma Services Announces Further Expansion in San Diego to Maintain Industry-Leading Quality, Service and Flexibility

PCI Pharma Services

PCI secures third site for Clinical Trials storage, central logistics and distribution center

Philadelphia, PA – June 4, 2019 PCI Pharma Services (PCI), a leading biopharmaceutical outsourcing services provider, has announced the growth of its West Coast Clinical operations with expansion into its third facility in San Diego.

The San Diego site is one of PCI’s eight global Clinical locations across the US, EU and Asia Pacific regions – supporting Clinical Trials in more than 100 countries around the world.

PCI’s new two-story 38,000 sq ft state of the art facility – located less than a mile from its existing San Diego campus – will serve as PCI’s main storage, logistics and distribution center on the West Coast. Beyond controlled room temperature, the building will be equipped for Cold Chain requirements for 2-8°C, -20°C, and -80°C with expanded ultra-low freezer capabilities, as well as cryogenic liquid nitrogen storage at -196°C.

The site expansion project will be completed and validated during the fourth quarter of 2019.

PCI’s Mark Shepanski, Executive Director of Operations and Site Lead for San Diego, said: “Securing our third site in San Diego allows us to continue to provide industry-leading reliability, flexibility and quality in clinical supply management services.

“We began to investigate our requirements for the additional facility last year, anticipating our customers would eventually need additional storage space for their larger Clinical studies. As our customers experience continued success, we want to make sure we adapt and grow with them.”

This announcement is the latest reflecting PCI’s commitment to the continued development and expansion of its global clinical supply network in anticipation of future customer needs; a strategy which includes ongoing and considerable capital investment in facilities and increased capacity.

To find out more, please visit here.

About PCI
The global healthcare industry trusts PCI for the development solutions that increase their products' speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Leading technology and continued investment enables us to address global needs throughout the product life cycle — from preclinical development, clinical investigational studies, commercialization and ongoing supply. Our customers view us as an extension of their business and a collaborative partner, with the shared goal of improving patients' lives.

For more information, please visit www.pciservices.com or follow us on Twitter at @PCI_Social.

Contact
Tom Gosschalk / Carrie Lowe at BECG
T: +44 (0)20 3697 7647 / +44 (0)1962 893 913
phone +44 (0)1495 713 633
email sales@pciservices.com
web www.pciservices.com
email Wye Valley Business Park, Hay-on-Wye, HR3 5PG
 
Print this page
Send to a friend
   
spacer
News and Press Releases

CPI to showcase results from BioStreamline project developing novel biotherapeutics

CPI, a UK-based technology innovation centre and a founding member of the High Value Manufacturing Catapult, announced today that it will host an event in Darlington, UK on 26 June 2019 to disseminate the results of the £11.2M BioStreamline project to optimise the development of novel therapeutics. During the event, the project partners — Lonza Biologics, UCB Celltech, Sphere Fluidics, Horizon Discovery Group plc (Horizon), Alcyomics Ltd and CPI — will showcase the results and discuss the potential impact on overcoming some of the most significant shortcomings of the biologics supply chain.
More info >>


White Papers

Syringe siliconization

Gerresheimer AG

Ready-to-fill, i.e. sterile, prefillable glass syringes, are washed, siliconized, sterilized and packaged by the primary packaging manufacturer. They can then be filled by the pharmaceutical companies without any further processing. These days the majority of prefillable syringes are made of glass and the trend looks set to continue. The siliconization of the syringe barrel is an extremely important aspect of the production of sterile, prefillable glass syringes because the functional interaction of the glass barrel siliconization and the plunger stopper siliconization is crucial to the efficiency of the entire system. Both inadequate and excessive siliconization can cause problems in this connection. The use of modern technology can achieve an extremely uniform distribution of silicone oil in glass syringes with reduced quantities of silicone oil. Another option for minimizing the amount of free silicone oil in a syringe is the thermal fixation of the silicone oil on the glass surface in a process called baked-on siliconization. Plastic-based silicone oil-free or low-silicone oil prefillable syringe systems are a relatively new development. Silicone oil-free lubricant coatings for syringes are also currently in the development phase.
More info >>

Industry Events

INTERPHEX 2020

28-30 April 2020, Javits Center NYC


More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement